INDIANAPOLIS, Aug. 10, 2015 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with Diagnostic Laboratory Services of Aiea, Hawaii, that designates the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.
Established in 2002, Roche's MCOE program is designed to create an alliance network that enables non-competing regional laboratories across the U.S. to collaborate and capitalize on scientific knowledge in molecular testing and, in turn, help accelerate the advancement of new test methods and technology.
"Roche is very pleased to welcome Diagnostic Laboratory Services into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, commercial operations at Roche Diagnostics Corporation. "We value their expertise, especially in areas like microbiology and pathology, and look forward to working together to implement molecular technologies for the advancement of personalized medicine."
Diagnostic Laboratory Services is one of 33 labs in the U.S. that have received this recognition and joined in this strategic partnership with Roche. "Our physicians and patients will all benefit from the advanced molecular technologies that Roche's Center of Excellence concentrates on," said Richard Okazaki, president and CEO of Diagnostic Laboratory Services. "We are very pleased to be part of this strategic partnership."
As a nationally recognized Roche MCOE, the Diagnostic Laboratory Services molecular diagnostics laboratory will offer physicians and patients some of the latest and most advanced molecular technologies, such as Roche's cobas CT/NG v2.0 Test, a qualitative in-vitro test to help physicians detect chlamydia and gonorrhea infections and subsequently treat infected symptomatic and asymptomatic patients.
About Diagnostic Laboratory Services
Diagnostic Laboratory Services, Inc., is a medical testing laboratory that offers a comprehensive range of routine and esoteric testing services and the most sophisticated forensic toxicology and substance abuse testing services in the State of Hawaii. The company employs more than 700 people and has locations throughout Hawaii, Saipan and Guam.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-eight medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.
In 2014, the Roche Group employed 88,500 people worldwide, invested 8.9 billion Swiss francs in R&D and posted sales of 47.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com or www.usdiagnostics.roche.com.
COBAS is a trademark of Roche. All trademarks mentioned in this release are protected by law.
For further information, please contact:
Senior Director, Communications
Roche Diagnostics Corporation
Indianapolis, Indiana USA
Diagnostic Laboratory Services, Inc.
Piia M. Aarma
Pineapple Tweed PR & Marketing
(808) 737-1904 (o)
SOURCE Roche Diagnostics